{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:08:19Z","timestamp":1789949299280,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R29 CA60050"],"award-info":[{"award-number":["R29 CA60050"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["8UL1TR000090-05"],"award-info":[{"award-number":["8UL1TR000090-05"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH funding.","doi-asserted-by":"publisher","award":["K12"],"award-info":[{"award-number":["K12"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.mce.2014.12.028","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T12:49:48Z","timestamp":1420548588000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer"],"prefix":"10.1016","volume":"402","author":[{"given":"Drew R.","family":"Oostra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam B.","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel E.","family":"Reinbolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueliang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.mce.2014.12.028_bib0010","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S1359-6446(02)02260-2","article-title":"Osteoprotegerin and bone loss associated with spaceflight","volume":"7","author":"Bateman","year":"2002","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.mce.2014.12.028_bib0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S8756-3282(02)00953-5","article-title":"The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts","volume":"32","author":"Bord","year":"2003","journal-title":"Bone"},{"issue":"Suppl. 1","key":"10.1016\/j.mce.2014.12.028_bib0020","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9","author":"Boyce","year":"2007","journal-title":"Arthritis Res. Ther"},{"issue":"2","key":"10.1016\/j.mce.2014.12.028_bib0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch. Biochem. Biophys"},{"issue":"5","key":"10.1016\/j.mce.2014.12.028_bib0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/08860220500198698","article-title":"Osteoprotegerin and bone mineral density in hemodiafiltration patients","volume":"27","author":"Crisafulli","year":"2005","journal-title":"Ren. Fail"},{"issue":"8","key":"10.1016\/j.mce.2014.12.028_bib0035","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.mce.2014.12.028_bib0040","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mpo.10341","article-title":"Management of osteoporosis due to ovarian failure","volume":"41","author":"Eastell","year":"2003","journal-title":"Med. Pediatr. Oncol"},{"issue":"6","key":"10.1016\/j.mce.2014.12.028_bib0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-944548","article-title":"Altered osteoprotegerin\/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet","volume":"38","author":"Fiore","year":"2006","journal-title":"Horm. Metab. Res"},{"issue":"9768","key":"10.1016\/j.mce.2014.12.028_bib0050","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.mce.2014.12.028_bib0055","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1515\/JPEM.2009.22.12.1105","article-title":"Relationships between osteoprotegerin (OPG), receptor activator of nuclear factor kappaB ligand (RANKL), and growth hormone (GH) secretory status in short children","volume":"22","author":"Flint","year":"2009","journal-title":"J. Pediatr. Endocrinol. Metab"},{"issue":"12","key":"10.1016\/j.mce.2014.12.028_bib0060","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos. Int"},{"issue":"9","key":"10.1016\/j.mce.2014.12.028_bib0065","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol"},{"issue":"20 Pt 2","key":"10.1016\/j.mce.2014.12.028_bib0070","doi-asserted-by":"crossref","first-page":"6309s","DOI":"10.1158\/1078-0432.CCR-06-0652","article-title":"Skeletal complications of breast cancer therapies","volume":"12","author":"Hirbe","year":"2006","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.mce.2014.12.028_bib0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00383-009-2325-y","article-title":"Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia","volume":"25","author":"Honsawek","year":"2009","journal-title":"Pediatr. Surg. Int"},{"issue":"2","key":"10.1016\/j.mce.2014.12.028_bib0080","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10549-012-2084-7","article-title":"Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy","volume":"134","author":"Jacot","year":"2012","journal-title":"Breast Cancer Res. Treat"},{"issue":"12","key":"10.1016\/j.mce.2014.12.028_bib0085","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","article-title":"Minireview: the OPG\/RANKL\/RANK system","volume":"142","author":"Khosla","year":"2001","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.mce.2014.12.028_bib0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1615\/CritRevEukarGeneExpr.v19.i1.30","article-title":"Action of RANKL and OPG for osteoclastogenesis","volume":"19","author":"Kobayashi","year":"2009","journal-title":"Crit. Rev. Eukaryot. Gene Expr"},{"issue":"4","key":"10.1016\/j.mce.2014.12.028_bib0095","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8","article-title":"Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer","volume":"39","author":"Koyama","year":"1977","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.mce.2014.12.028_bib0100","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S8756-3282(03)00090-5","article-title":"Serum levels of osteoprotegerin increase with age in a healthy adult population","volume":"32","author":"Kudlacek","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.mce.2014.12.028_bib0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/978-0-387-89520-8_9","article-title":"RANK(L) as a key target for controlling bone loss","volume":"647","author":"Leibbrandt","year":"2009","journal-title":"Adv. Exp. Med. Biol"},{"issue":"5","key":"10.1016\/j.mce.2014.12.028_bib0110","first-page":"986","article-title":"Osteoprotegerin (OPG)\/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG\/RANK-L in bone injury?","volume":"31","author":"Masi","year":"2004","journal-title":"J. Rheumatol"},{"issue":"3","key":"10.1016\/j.mce.2014.12.028_bib0115","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin","volume":"247","author":"Mizuno","year":"1998","journal-title":"Biochem. Biophys. Res. Commun"},{"issue":"6","key":"10.1016\/j.mce.2014.12.028_bib0120","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1507\/endocrj.K07-034","article-title":"The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa","volume":"54","author":"Ohwada","year":"2007","journal-title":"Endocr. J."},{"issue":"4","key":"10.1016\/j.mce.2014.12.028_bib0125","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J. Clin. Oncol"},{"issue":"4","key":"10.1016\/j.mce.2014.12.028_bib0130","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/0002-9343(81)90205-9","article-title":"Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease","volume":"71","author":"Schilsky","year":"1981","journal-title":"Am. J. Med"},{"key":"10.1016\/j.mce.2014.12.028_bib0135","first-page":"101","article-title":"Late effects of adjuvant therapy for breast cancer","volume":"16","author":"Shapiro","year":"1994","journal-title":"J. Natl. Cancer Inst. Monogr"},{"issue":"14","key":"10.1016\/j.mce.2014.12.028_bib0140","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J. Clin. Oncol"},{"issue":"5","key":"10.1016\/j.mce.2014.12.028_bib0145","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","article-title":"Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809","volume":"47","author":"Shapiro","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.mce.2014.12.028_bib0150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.mce.2014.12.028_bib0155","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nrc1992","article-title":"Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants","volume":"6","author":"Stearns","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.mce.2014.12.028_bib0160","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0002-9378(81)90413-0","article-title":"Ovarian failure in long-term survivors of childhood malignancy","volume":"139","author":"Stillman","year":"1981","journal-title":"Am. J. Obstet. Gynecol"},{"issue":"35","key":"10.1016\/j.mce.2014.12.028_bib0165","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol"},{"issue":"2","key":"10.1016\/j.mce.2014.12.028_bib0170","first-page":"CR96","article-title":"Does serum osteoprotegerin level relate to fragility fracture in elderly women with low vitamin D status?","volume":"16","author":"Sypniewska","year":"2010","journal-title":"Med. Sci. Monit"},{"issue":"2","key":"10.1016\/j.mce.2014.12.028_bib0175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01.coc.0000251398.57630.4f","article-title":"The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane","volume":"30","author":"Tham","year":"2007","journal-title":"Am. J. Clin. Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.mce.2014.12.028_bib0180","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.3816\/CBC.2005.s.006","article-title":"Strategies to prevent chemotherapy-induced bone loss in women with breast cancer","volume":"5","author":"Theriault","year":"2005","journal-title":"Clin. Breast Cancer"},{"issue":"5","key":"10.1016\/j.mce.2014.12.028_bib0185","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bone.2003.08.001","article-title":"Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover","volume":"33","author":"Uemura","year":"2003","journal-title":"Bone"},{"issue":"22","key":"10.1016\/j.mce.2014.12.028_bib0190","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJM197311292892202","article-title":"Cyclophosphamide-induced ovarian failure","volume":"289","author":"Warne","year":"1973","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.mce.2014.12.028_bib0195","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12178-009-9046-7","article-title":"RANK, RANKL and osteoprotegerin in bone biology and disease","volume":"2","author":"Wright","year":"2009","journal-title":"Curr. Rev. Musc. Med"},{"issue":"4","key":"10.1016\/j.mce.2014.12.028_bib0200","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1359\/jbmr.1999.14.4.518","article-title":"Immunological characterization of circulating osteoprotegerin\/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis","volume":"14","author":"Yano","year":"1999","journal-title":"J. Bone Miner. Res"}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720715000064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720715000064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T04:58:55Z","timestamp":1566190735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720715000064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":39,"alternative-id":["S0303720715000064"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2014.12.028","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2014.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}